Ascendia Founder and CEO Jim Huang, PhD. is featured in the March 2020 issue of Drug Development & Delivery. Dr. Huang is quoted in the media outlet’s Special Feature on bioavailability and solubility and explains how a tailored formulation can rapidly transition compounds from preclinical to clinic.
In the article, Dr. Huang explains how a pharma client wanted to develop a human formulation for an insoluble small molecule and supply GMP CTM for human clinical trials within 4-5 months. Ascendia developed three prototype formulations that were tested in animal models within three months of project initiation that resulted in a 3-, 5-, and 10-fold enhancement in bioavailability
Read the entire article on the Drug Development & Delivery website.